Search
Close this search box.

A randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis loco regionally advanced HPV-associated oropharyngeal squamous cell carcinoma

The excellent prognosis of patients with low-risk human papillomavirus (HPV)- associated oropharyngeal squamous cell carcinoma has led to concerns about overtreatment and excessive toxicity with radiation therapy and cisplatin, leading to interest in de-intensification trials. We investigated whether cetuximab, an epidermal growth factor receptor targeting antibody, when combined with radiation therapy would result in a decrease in symptom burden and toxicity with similar efficacy compared with weekly cisplatin.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

189

Closing Date of Accrual

7 June 2018

Trial Chairperson

Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC, Australia

A/Prof June Corry, GenesisCare St Vincents, NSW, Australia

Trial Contact

Annie.Ko@petermac.org

Clinical Trial Registration

Related Post

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof